Effect of low-dose thalidomide on dopaminergic neuronal differentiation of human neural progenitor cells: A combined study of metabolomics and morphological analysis

NeuroToxicology

Volumn 33, Issue 5, 2012, Pages 1375-1380

  Qin, Xian Yang ^a,b   Akanuma, Hiromi ^a   Wei, Feifei ^c   Nagano, Reiko ^a   Zeng, Qin ^a   Imanishi, Satoshi ^d   Ohsako, Seiichiroh ^d   Yoshinaga, Jun ^b   Yonemoto, Junzo ^a   Tanokura, Masaru ^c   Sone, Hideko ^a  

^a NATIONAL INSTITUTE FOR ENVIRONMENTAL STUDIES   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

CE TOFMS; Dopamine; Metabolomics; Neuronal differentiation; Thalidomide

Indexed keywords

DOPAMINE; GLUTATHIONE; METHIONINE; PHENYLALANINE; THALIDOMIDE; TYROSINE; TYROSINE 3 MONOOXYGENASE;

AMINO ACID METABOLISM; ARTICLE; CELL COUNT; CELL METABOLISM; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; HUMAN; HUMAN CELL; METABOLOMICS; NERVE CELL DIFFERENTIATION; NEURAL STEM CELL; PRIORITY JOURNAL;

AMINO ACIDS; CAPILLARY ELECTROCHROMATOGRAPHY; CELL DIFFERENTIATION; CELL LINE; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBRYONIC STEM CELLS; GLUTATHIONE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICROTUBULE-ASSOCIATED PROTEINS; PRINCIPAL COMPONENT ANALYSIS; TANDEM MASS SPECTROMETRY; THALIDOMIDE; TYROSINE 3-MONOOXYGENASE;

EID: 84867231227     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2012.08.016     Document Type: Article

References (39)

1. Barlogie B., Desikan R., Eddlemon P., Spencer T., Zeldis J., Munshi N., et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001, 98:492-494.
2. Beal M.F., Hyman B.T., Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?. Trends Neurosci 1993, 16:125-131.
3. Breier J.M., Gassmann K., Kayser R., Stegeman H., De Groot D., Fritsche E., et al. Neural progenitor cells as models for high-throughput screens of developmental neurotoxicity: state of the science. Neurotoxicol Teratol 2010, 32:4-15.
4. Breier J.M., Radio N.M., Mundy W.R., Shafer T.J. Development of a high-throughput screening assay for chemical effects on proliferation and viability of immortalized human neural progenitor cells. Toxicol Sci 2008, 105:119-133.
5. Caiazzo M., Dell'Anno M.T., Dvoretskova E., Lazarevic D., Taverna S., Leo D., et al. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature 2011, 476:224-227.
6. Ebert A.D., Beres A.J., Barber A.E., Svendsen C.N. Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson's disease. Exp Neurol 2008, 209:213-223.
7. Franks M.E., Macpherson G.R., Figg W.D. Thalidomide. Lancet 2004, 363:1802-1811.
8. Gimenez-Llort L., Ahlbom E., Dare E., Vahter M., Ogren S., Ceccatelli S. Prenatal exposure to methylmercury changes dopamine-modulated motor activity during early ontogeny: age and gender-dependent effects. Environ Toxicol Pharmacol 2001, 9:61-70.
9. Glaser C.B., Yamin G., Uversky V.N., Fink A.L. Methionine oxidation, alpha-synuclein and Parkinson's disease. Biochim Biophys Acta 2005, 1703:157-169.
10. James S.J., Cutler P., Melnyk S., Jernigan S., Janak L., Gaylor D.W., et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 2004, 80:1611-1617.
11. Jeon S.M., Cheon S.M., Bae H.R., Kim J.W., Kim S.U. Selective susceptibility of human dopaminergic neural stem cells to dopamine-induced apoptosis. Exp Neurobiol 2010, 19:155-164.
12. Kamikawa R., Ikawa K., Morikawa N., Asaoku H., Iwato K., Sasaki A. The pharmacokinetics of low-dose thalidomide in Japanese patients with refractory multiple myeloma. Biol Pharm Bull 2006, 29:2331-2334.
13. Kim J.H., Scialli A.R. Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci 2011, 122:1-6.
14. Kitiyanant N., Kitiyanant Y., Svendsen C.N., Thangnipon W. BDNF-, IGF-1- and GDNF-secreting human neural progenitor cells rescue amyloid beta-induced toxicity in cultured rat septal neurons. Neurochem Res 2011, 37:143-152.
15. Knobloch J., Reimann K., Klotz L.O., Ruther U. Thalidomide resistance is based on the capacity of the glutathione-dependent antioxidant defense. Mol Pharm 2008, 5:1138-1144.
16. Knobloch J., Schmitz I., Gotz K., Schulze-Osthoff K., Ruther U. Thalidomide induces limb anomalies by PTEN stabilization, Akt suppression, and stimulation of caspase-dependent cell death. Mol Cell Biol 2008, 28:529-538.
17. Lapainis T., Rubakhin S.S., Sweedler J.V. Capillary electrophoresis with electrospray ionization mass spectrometric detection for single-cell metabolomics. Anal Chem 2009, 81:5858-5864.
18. Lenz W. A short history of thalidomide embryopathy. Teratology 1988, 38:203-215.
19. Lunn J.S., Sakowski S.A., Hur J., Feldman E.L. Stem cell technology for neurodegenerative diseases. Ann Neurol 2011, 70:353-361.
20. Ma Y., Peng S., Dhawan V., Eidelberg D. Dopamine cell transplantation in Parkinson's disease: challenge and perspective. Br Med Bull 2011, 100:173-189.
21. Maletic-Savatic M., Vingara L.K., Manganas L.N., Li Y., Zhang S., Sierra A., et al. Metabolomics of neural progenitor cells: a novel approach to biomarker discovery. Cold Spring Harb Symp Quant Biol 2008, 73:389-401.
22. Matthews S.J., McCoy C. Thalidomide: a review of approved and investigational uses. Clin Ther 2003, 25:342-395.
23. Ohashi Y., Hirayama A., Ishikawa T., Nakamura S., Shimizu K., Ueno Y., et al. Depiction of metabolome changes in histidine-starved Escherichia coli by CE-TOFMS. Mol Biosyst 2008, 4:135-147.
24. Qin X.Y., Fukuda T., Yang L., Zaha H., Akanuma H., Zeng Q., et al. Effects of bisphenol A exposure on the proliferation and senescence of normal human mammary epithelial cells. Cancer Biol Ther 2012, 13:296-306.
25. Qin X.Y., Kojima Y., Mizuno K., Ueoka K., Muroya K., Miyado M., et al. Identification of novel low-dose bisphenol a targets in human foreskin fibroblast cells derived from hypospadias patients. PLoS One 2012, 7:e36711.
26. Qin X.Y., Wei F., Yoshinaga J., Yonemoto J., Tanokura M., Sone H. siRNA-mediated knockdown of aryl hydrocarbon receptor nuclear translocator 2 affects hypoxia-inducible factor-1 regulatory signaling and metabolism in human breast cancer cells. FEBS Lett 2011, 585:3310-3315.
27. Ryu J.K., Cho T., Wang Y.T., McLarnon J.G. Neural progenitor cells attenuate inflammatory reactivity and neuronal loss in an animal model of inflamed AD brain. J Neuroinflamm 2009, 6:39.
28. Sanchez-Pernaute R., Lee H., Patterson M., Reske-Nielsen C., Yoshizaki T., Sonntag K.C., et al. Parthenogenetic dopamine neurons from primate embryonic stem cells restore function in experimental Parkinson's disease. Brain 2008, 131:2127-2139.
29. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965, 6:303-306.
30. Shin S., Dalton S., Stice S.L. Human motor neuron differentiation from human embryonic stem cells. Stem Cells Dev 2005, 14:266-269.
31. Soga T., Ueno Y., Naraoka H., Ohashi Y., Tomita M., Nishioka T. Simultaneous determination of anionic intermediates for Bacillus subtilis metabolic pathways by capillary electrophoresis electrospray ionization mass spectrometry. Anal Chem 2002, 74:2233-2239.
32. Sugimoto M., Hirayama A., Robert M., Abe S., Soga T., Tomita M. Prediction of metabolite identity from accurate mass, migration time prediction and isotopic pattern information in CE-TOFMS data. Electrophoresis 2010, 31:2311-2318.
33. Sugimoto M., Wong D.T., Hirayama A., Soga T., Tomita M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics 2010, 6:78-95.
34. Takada K., Munemasa Y., Kuribayashi J., Fujino H., Kitaoka Y. Protective effect of thalidomide against N-methyl-d-aspartate-induced retinal neurotoxicity. J Neurosci Res 2011, 89:1596-1604.
35. Teo S.K., Stirling D.I., Zeldis J.B. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discov Today 2005, 10:107-114.
36. Uhl K., Cox E., Rogan R., Zeldis J.B., Hixon D., Furlong L.A., et al. Thalidomide use in the US: experience with pregnancy testing in the S.T.E.P.S. programme. Drug Saf 2006, 29:321-329.
37. Vianna F.S., Lopez-Camelo J.S., Leite J.C., Sanseverino M.T., Dutra Mda G., Castilla E.E., et al. Epidemiological surveillance of birth defects compatible with thalidomide embryopathy in Brazil. PLoS One 2011, 6:e21735.
38. Wells P.G., Bhuller Y., Chen C.S., Jeng W., Kasapinovic S., Kennedy J.C., et al. Molecular and biochemical mechanisms in teratogenesis involving reactive oxygen species. Toxicol Appl Pharmacol 2005, 207:354-366.
39. Zimmer B., Schildknecht S., Kuegler P.B., Tanavde V., Kadereit S., Leist M. Sensitivity of dopaminergic neuron differentiation from stem cells to chronic low-dose methylmercury exposure. Toxicol Sci 2011, 121:357-367.